NasdaqGS:IMCRBiotechs
Is Immunocore Holdings (IMCR) Undervalued After Stronger Revenue And Profitability Results?
Immunocore Holdings (IMCR) reported its second quarter and six month results on August 6, 2026, with higher revenue and a move from a net loss to net income over the half year period.
See our latest analysis for Immunocore Holdings.
At a share price of US$34.21, Immunocore Holdings shows a 90 day share price return of 18.25%, while the 1 year total shareholder return of 5.88% contrasts with a 3 year total shareholder return that is down 42.85%. This suggests that momentum has been rebuilding...